Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cogent Biosciences, Inc. (COGT)
:COGT
RESEARCH TOOLSreports
COGT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.73 - $12.61
Previous CloseN/A
Volume181.15K
Average Volume (3M)1.46M
Market Cap
$893.64M
Enterprise Value$982.70M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Mar 18, 2025EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.48
Shares Outstanding110,461,730
10 Day Avg. Volume867,782
30 Day Avg. Volume1,460,421
Standard Deviation0.67
R-Squared0.02
Alpha0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)940.67
Price to Cash Flow (P/CF)-4.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-273.88
Enterprise Value/Ebitda-3.82
Forecast
1Y Price Target
$16.86Price Target Upside110.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsCogent presented favorable Part 1 results from the Phase 3 Peak trial, which is evaluating bezuclastinib + sunitinib in 2L GIST.
Market OpportunityThe results continue to support that bezuclastinib has a differentiated profile within SM that could allow for a relevant market opportunity to be captured in this estimated >$2Bn market.
Safety And EfficacyThe updates are positive for COGT, especially for ASM, reinforcing the comparable efficacy and superior safety profile in comparison to Ayvakit.
Bears Say
Safety ConcernsSome investors may remain concerned about liver toxicity and dose optimization, despite the DILI reclassification.
Safety ProfileConcerns have been raised regarding the utilization of Bezuclastinib in non-advanced systemic mastocytosis due to its less favorable safety profile compared to Ayvakit.
Stock Rating DowngradeA significant proportion of patients experienced AST/ALT elevations, hair color changes, and diarrhea, which contributed to the downgrade of the stock rating.
---
Ownership Overview
11.78% Insiders
17.43% Mutual Funds
0.68% Other Institutional Investors
57.79% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
COGT FAQ
What was Cogent Biosciences, Inc.’s price range in the past 12 months?
Cogent Biosciences, Inc. lowest stock price was $5.73 and its highest was $12.61 in the past 12 months.
What is Cogent Biosciences, Inc.’s market cap?
Cogent Biosciences, Inc.’s market cap is $893.64M.
When is Cogent Biosciences, Inc.’s upcoming earnings report date?
Cogent Biosciences, Inc.’s upcoming earnings report date is Mar 18, 2025 which is in 23 days.
How were Cogent Biosciences, Inc.’s earnings last quarter?
Cogent Biosciences, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.566 by -$0.074.
Is Cogent Biosciences, Inc. overvalued?
According to Wall Street analysts Cogent Biosciences, Inc.’s price is currently Undervalued.
Does Cogent Biosciences, Inc. pay dividends?
Cogent Biosciences, Inc. does not currently pay dividends.
What is Cogent Biosciences, Inc.’s EPS estimate?
Cogent Biosciences, Inc.’s EPS estimate is -0.59.
How many shares outstanding does Cogent Biosciences, Inc. have?
Cogent Biosciences, Inc. has 110,461,730 shares outstanding.
What happened to Cogent Biosciences, Inc.’s price movement after its last earnings report?
Cogent Biosciences, Inc. reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.566. Following the earnings report the stock price went down -0.192%.
Which hedge fund is a major shareholder of Cogent Biosciences, Inc.?
Currently, no hedge funds are holding shares in COGT
---
Cogent Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.86 (110.75% Upside)
$16.86 (110.75% Upside)
Blogger Sentiment
Bullish
COGT Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.54%
12-Months-Change
Fundamentals
Return on Equity
-78.47%
Trailing 12-Months
Asset Growth
8.04%
Trailing 12-Months
Company Description
Cogent Biosciences, Inc.
Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.
---
COGT Stock 12 Month Forecast
Average Price Target
$16.86
▲(110.75% Upside)
Technical Analysis
Best Analysts Covering COGT
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
+0.93%
reiterated a buy rating last month
Copying Robert Burns's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of +0.93% per trade.
---